Cutia Therapeutics' CU-30101 Marketing Authorization Application Accepted by National Medical Products Administration for Review

Reuters

Jun 27, 2025

Cutia <a href="https://laohu8.com/S/LENZ">Therapeutics</a>' CU-30101 Marketing Authorization Application Accepted by National Medical Products Administration for Review

Cutia Therapeutics has announced the acceptance of their drug marketing authorization application for CU-30101 by the National Medical Products Administration in July 2024. This follows the successful completion of a Phase III clinical trial for CU-30101, a localized topical lidocaine and tetracaine cream designed for topical anesthesia operations. The trial results have been recognized for presentation at the 30th Annual Meeting of the Chinese Society of Dermatology, highlighting the company's influence and advanced standing in dermatology. There is no assurance, however, that CU-30101 will be successfully marketed, and stakeholders are advised to exercise caution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics published the original content used to generate this news brief on June 27, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2546754735"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546754735\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2546754735?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-27 06:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546754735","market":"nz","top_or_hot":-1,"title":"Cutia Therapeutics' CU-30101 Marketing Authorization Application Accepted by National Medical Products Administration for Review","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cutia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' CU-30101 Marketing Authorization Application Accepted by National Medical Products Administration for Review\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cutia Therapeutics has announced the acceptance of their drug marketing authorization application for CU-30101 by the National Medical Products Administration in July 2024. This follows the successful completion of a Phase III clinical trial for CU-30101, a localized topical lidocaine and tetracaine cream designed for topical anesthesia operations. The trial results have been recognized for presentation at the 30th Annual Meeting of the Chinese Society of Dermatology, highlighting the company's influence and advanced standing in dermatology. There is no assurance, however, that CU-30101 will be successfully marketed, and stakeholders are advised to exercise caution.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics published the original content used to generate this news brief on June 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cutia Therapeutics' CU-30101 Marketing Authorization Application Accepted by National Medical Products Administration for Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCutia Therapeutics' CU-30101 Marketing Authorization Application Accepted by National Medical Products Administration for Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-27 06:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cutia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' CU-30101 Marketing Authorization Application Accepted by National Medical Products Administration for Review\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cutia Therapeutics has announced the acceptance of their drug marketing authorization application for CU-30101 by the National Medical Products Administration in July 2024. This follows the successful completion of a Phase III clinical trial for CU-30101, a localized topical lidocaine and tetracaine cream designed for topical anesthesia operations. The trial results have been recognized for presentation at the 30th Annual Meeting of the Chinese Society of Dermatology, highlighting the company's influence and advanced standing in dermatology. There is no assurance, however, that CU-30101 will be successfully marketed, and stakeholders are advised to exercise caution.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics published the original content used to generate this news brief on June 27, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL40sdrl:1","article_id":"2546754735","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546754735","pubTimestamp":1750975634,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cutia Therapeutics' CU-30101 Marketing Authorization Application Accepted by National Medical Products Administration for Review. Cutia Therapeutics has announced the acceptance of their drug marketing authorization application for CU-30101 by the National Medical Products Administration in July 2024. This follows the successful completion of a Phase III clinical trial for CU-30101, a localized topical lidocaine and tetracaine cream designed for topical anesthesia operations. The trial results have been recognized for presentation at the 30th Annual Meeting of the Chinese Society of Dermatology, highlighting the company's influence and advanced standing in dermatology. There is no assurance, however, that CU-30101 will be successfully marketed, and stakeholders are advised to exercise caution.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02487":"科笛-B"},"translate_title":"Cutia Therapeutics CU-30101上市许可申请获国家药品监督管理局受理审评","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02487":0.9},"content_text":"Cutia Therapeutics' CU-30101 Marketing Authorization Application Accepted by National Medical Products Administration for Review\n    \n\n        Cutia Therapeutics has announced the acceptance of their drug marketing authorization application for CU-30101 by the National Medical Products Administration in July 2024. This follows the successful completion of a Phase III clinical trial for CU-30101, a localized topical lidocaine and tetracaine cream designed for topical anesthesia operations. The trial results have been recognized for presentation at the 30th Annual Meeting of the Chinese Society of Dermatology, highlighting the company's influence and advanced standing in dermatology. There is no assurance, however, that CU-30101 will be successfully marketed, and stakeholders are advised to exercise caution.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cutia Therapeutics published the original content used to generate this news brief on June 27, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}